Source: Eur Respir J 2012; 39: 777-780
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ohashi K., Sato A., Takada T., Arai T., Kasahara Y., Hojo M., Nei T., Nakayama H., Motoi N., Urano S., Eda R., Yokoba M., Tsuchihashi Y., Nasuhara Y., Ishii H., Ebina M., Yamaguchi E., Inoue Y., Nakata K., Tazawa R.. Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. Eur Respir J 2012; 39: 777-780

Member's Comments

No comment yet.

Related content which might interest you: Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020 Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009 Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Lymphocytes populations in bloods and lungs in patients with auto-immune pulmonary alveolar proteinosis Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011 The role of apoptosis in idiopathic pulmonary alveolar proteinosis Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 The benefits of whole lung lavage in pulmonary alveolar proteinosis Source: Eur Respir J 2004; 23: 503-505 Year: 2004 Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency Source: Eur Respir J 2016; 48: 1510-1514 Year: 2016 Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis Source: Eur Respir J, 49 (5) 1700178; 10.1183/13993003.00178-2017 Year: 2017 Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis Source: Eur Respir J, 49 (5) 1700407; 10.1183/13993003.00407-2017 Year: 2017